Micromagnetic resonance relaxometry (μMRR) for rapid and non-invasive detection of mesenchymal stem cell senescence
Patent Information
- Application Number
- JP2024525234
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-28
- Filing Date
- 2022-10-27
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2042-10-27
AI Technical Summary
Current methods for detecting senescent cells in cell cultures are invasive, time-consuming, and not suitable for quality control during cell manufacturing, particularly affecting the efficacy of mesenchymal stem cells in regenerative medicine.
A non-invasive method using micromagnetic resonance relaxometry (μMRR) to detect senescent cells by measuring transverse relaxation times (T2) of protons, correlating with ferritin concentration, allowing rapid identification and separation of senescent cells using magnetic resonance relaxometry devices and cell separation techniques.
The μMRR method provides rapid, accurate detection of senescent cells, correlating well with traditional assays, enabling effective enrichment of stem cells for improved therapeutic efficacy by reducing senescent cell numbers.
Abstract
Description
[Technical field]
[0001] (Priority Claim) This application claims priority to U.S. Provisional Application No. 63 / 272,738, filed October 28, 2021, which is incorporated by reference in its entirety.
[0002] (Technical field) The present invention provides systems and methods for non-invasive detection. [Background technology]
[0003] Cellular senescence is a cellular state in which aging and other external or internal conditions lead to cell cycle withdrawal accompanied by genetic, metabolic, and morphological changes in cells (Reference 1). Although senescence can be important for preventing cancer development and tumor progression (References 2-5), the accumulation of senescent cells in the body can have deleterious effects, especially in age-related diseases such as neurodegeneration, cardiovascular disease, osteoarthritis, renal dysfunction, nonalcoholic fatty liver disease, and type 2 diabetes (References 3, 6, and 7). Cells with senescent characteristics are often present in tissues affected by age-related diseases, and their detection and elimination are major goals of medical intervention (Reference 2). In senescent cells, the expression of genes involved in DNA replication, DNA repair, and the cell cycle is reduced (Reference 8). In addition, senescent cells exhibit senescence-associated secretory phenomena (SASP), which cause changes in the tissue microenvironment, local or systemic inflammation, and disruption of normal tissue architecture, resulting in resistance of senescent cells to immune clearance (References 3, 6, and 9). Apart from aging, tumor-associated stresses such as DNA damage (Ref. 10), reactive oxygen species (ROS) (Ref. 11), activation of certain oncogenes (Ref. 12), and exposure to interferon-β (Ref. 13) can also induce cellular senescence (Ref. 2). Summary of the Invention [Means for solving the problem]
[0004] (overview) The presence of senescent cells in in vitro cultures of adult mesenchymal stromal cells (MSCs) has called into question their clinical utility in regenerative medicine and cell therapy. A method for non-invasive and rapid detection of senescent cells in heterogeneous cell cultures using microscale magnetic resonance relaxometry (μMRR) and detection systems has been reported. For example, T2 relaxation times measured with μMRR have been shown to be strongly correlated with the percentage of senescent cells under diverse conditions, including different passages and donors, MSCs size-sorted by an inertial spiral microfluidic device, and senescence-induced MSCs. μMRR measurements also showed good correlation with traditional assays for senescence detection, which often lead to the destruction of cells. Because the presence of senescent cells can affect the multilineage differentiation capacity and quality of MSCs, the μMRR assay and system described herein are promising, non-invasive, and rapid critical quality analysis methods for improving the efficacy of MSCs for patients.
[0005] Here we describe a rapid and non-invasive detection of cellular senescence based on the transverse relaxation of protons using micromagnetic resonance relaxometry (μMRR).
[0006] In one embodiment, a method for detecting senescent cells can include loading a liquid sample containing a plurality of cells into a sensor, placing the sensor containing the liquid sample in a detection coil of a magnetic resonance relaxometry device, and determining a T2 value to detect the amount of senescent cells in the liquid sample. The sensor can be a tube or a chamber.
[0007] In another aspect, a method of improving the availability of stem or progenitor cells to a patient can include detecting senescent cells in a sample according to the methods described herein and enriching the cells in the sample to reduce the number of senescent cells in the sample.
[0008] In another aspect, a system for detecting senescent cells can include a magnetic resonance relaxometry device configured to detect an amount of senescent cells in a liquid sample, and a cell separation device that reduces the amount of senescent cells in the liquid sample based on an output from the magnetic resonance relaxometry device. In certain circumstances, the liquid sample can be taken from a cell batch. The cell separation device can remove senescent cells from the cell batch based on detecting the amount of senescent cells.
[0009] In certain circumstances, the magnetic resonance relaxometry device can be configured to measure the T2 value to detect the amount of senescent cells in the liquid sample.
[0010] In certain circumstances, the amount of senescent cells in a liquid sample may be proportional to the concentration of ferritin in the liquid sample.
[0011] In certain circumstances, the magnetic resonance relaxometry device can be configured to measure the T2 value to detect the amount of senescent cells, and the Fe in the liquid sample. 3+ This includes quantifying the amount of.
[0012] In certain circumstances, the amount of senescent cells in a liquid sample may be determined in comparison to a reference sample.
[0013] In certain circumstances, the amount of senescent cells in a liquid sample may be proportional to the concentration of ferritin in the liquid sample.
[0014] In certain circumstances, determining the T2 value to detect the amount of senescent cells involves the use of Fe in the liquid sample. 3+ The method may include quantifying the amount of.
[0015] In certain circumstances, the magnetic resonance relaxometry device may include a radio frequency probe.
[0016] In certain circumstances, the T1 relaxation time can be used in combination with the T2 value to determine whether senescent cells are present in a sample.
[0017] In certain circumstances, determining the T1 or T2 value may involve delivering a pulse train for a period of less than one minute.
[0018] In certain circumstances, determining the T1 or T2 value may involve acquiring and averaging between 2 and 70 scans.
[0019] In certain circumstances, T2 levels can decrease as the number of senescent cells increases.
[0020] In certain circumstances, the cells may include stem or progenitor cells. For example, the stem or progenitor cells may include mesenchymal stromal cells (MSCs), hematopoietic stem cells (HSCs), or induced pluripotent stem cells (iPSCs).
[0021] In certain circumstances, the detection volume of a magnetic resonance relaxometry device may include a sample volume of less than about 1 μL, for example, the volume may be less than 0.1 μL, less than about 0.01 μL, less than about 0.001 μL, or less than about 0.0001 μL, and in certain circumstances, the volume may be between about 1 pL and 10 pL.
[0022] In certain circumstances, determining T2 may include measuring the paramagnetic or ferromagnetic ion content of the cells. The paramagnetic or ferromagnetic ions may include iron or copper.
[0023] In certain circumstances, concentrating the cells may include passing the sample through a cell separation device, thereby separating senescent cells from non-senescent cells in the sample.
[0024] In certain circumstances, the cell separation device may include a microfluidic cell sorter, an inertial focusing device, a microfluidic filtration device, a centrifugal flow device, a deterministic lateral displacement (DLD) chip, a tangential flow microfiltration device, or a combination thereof.
[0025] In certain circumstances, the cell separation device may include a microfluidic spiral path.
[0026] In certain circumstances, the liquid sample may be contained within a microcapillary.
[0027] Other aspects, embodiments, and features will become apparent from the following description, drawings, and claims. [Brief description of the drawings]
[0028] BRIEF DESCRIPTION OF THE DRAWINGS [Figure 1A] FIG. 1A shows a schematic diagram of a magnetic resonance relaxometry (MRR) apparatus. [Figure 1B] FIG. 1B shows a schematic diagram of a system including a magnetic resonance relaxometry (MRR) device and a cell separation device. [Diagram 2] Figure 2 shows the protocol to isolate senescent MSCs from expansion culture and detect their MRR. As shown in the figure, the spiral microfluidic device has one inlet and two outlets. MSC culture medium is pumped into the microfluidic device and sorted at a rate of 3.5 ml / min to collect large cells (22-26 μm) from the inner outlet, and cells are sorted again at a rate of 1.5 ml / min from the outer outlet to collect small and proliferating cells (11-15 μm) and medium-sized cells (15-22 μm). The normalized concentration of the sorted total cells is loaded into a microcapillary tube and analyzed by MRR. [Figure 3A] FIG. 3A shows a schematic diagram illustrating the different behavior of iron ions in normal and senescent cells. [Figure 3B] FIG. 3B illustrates a pulse sequence that can be used with the systems and methods described herein. [Figure 3C] FIG. 3C shows the MRR system and aging measurements. [Figure 4A] Figure 4A shows the separation of young / proliferating and senescent MSCs from an MSC expansion culture using the spiral microfluidic device. The MSC expansion culture is pumped through the microfluidic device and sorted at various speeds, and MSCs of different sizes are collected at the outlet. [Figure 4B] FIG. 4B shows the cell diameter (μm) of MSCs sorted using the spiral microfluidic sorting device. [Figure 4C] Figure 4C shows the mean T2 values (n=6) of unsorted and size-sorted MSCs from two donors using the spiral microfluidic device. Large cells (22-26 μm) were size-sorted MSCs collected in the first round of sorting, while medium cells (15-22 μm) and small cells (11-15 μm) were collected in the second round of sorting. Statistical analysis of unsorted-small cells (n=6, *P=0.001) and unsorted-large cells (n=6, *P=0.002) was performed by two-tailed T-test. [Figure 4D] Figure 4D shows the mRNA expression levels of unsorted and size-sorted MSCs, demonstrating overexpression of senescence markers P16 and P21 in large MSCs. [Figure 4E] Figure 4E shows that Luminex assays of unsorted and size-sorted MSCs from two different donors show overexpression of the senescence-associated secretory phenotype. [Figure 4F] Figure 4F shows β-galactosidase staining of unsorted and size-sorted MSCs, with the cytoplasm of senescent MSCs stained blue (black arrows). [Figure 5A] FIG. 5A shows the T2 values (n=3) of MSCs from different donors D1 to D5 (passage 3). [Figure 5B] Figure 5B shows images of multilineage differentiation (adipogenesis, osteogenesis, and chondrogenesis) of each MSC donor at passage 3. Osteogenic induction was confirmed by Alizarin Red S staining for calcium deposition, and adipogenic differentiation was confirmed by Oil Red O staining for detection of lipid droplets. Chondrogenic differentiation was confirmed by glycosaminoglycan staining with Safranin O. [Figure 5C] FIG. 5C shows the mean T2 values (n=3) of MSCs serially passaged from 3 to 8. [Figure 5D]FIG. 5D shows the relative mRNA expression values of P21 and P16 MSCs at passage P7 from the same donor compared with passage P4 as a control. [Figure 5E] FIG. 5E shows β-galactosidase staining of MSCs at passages P4, P6 and P8 from the same donor, with the cytoplasm of senescent MSCs stained blue (black arrows). [Figure 6A] Figure 6A shows immunofluorescence images of expanded MSCs as doxorubicin-treated MSCs from passages P3, P5, P6 and P3. Cells are stained with a senescence marker (γ-H2aX foci) that fluoresces red and a proliferation marker, 5-ethynyl-2'-deoxyuridine (Edu), that fluoresces green. Cell nuclei are counterstained with NucBlue (Hoechst 33342), which fluoresces blue (shown as DAPI) when bound to DNA. [Figure 6B] FIG. 6B shows β-galactosidase staining of MSCs at passages P3, P5 and P6, with the cytoplasm of senescent MSCs stained blue. [Figure 6C] [Figure 6D] Figures 6C and 6D show the proliferation (Pf) index (%) and senescence (Sn) index (%) calculated by counting the number of green and red fluorescent stainings relative to the number of blue fluorescent stainings in all images. A total of 10 images from each of the three repeated staining experiments in P3, P5, P6 and DOX-treated MSCs were used to calculate the Pf index (%) and Sn index (%) plotted in (Figure 6C) and (Figure 6D). [Figure 6E] FIG. 6E shows the relative mRNA expression levels of senescence-associated markers p16 and p21 in MSCs at different passages: P3, P5, and P6. [Figure 6F] Figure 6F shows the average T2 results (n=3) of P3, P5, P6 and DOX treatments. Statistical analysis of P3 vs. DOX (n=3) was performed by two-tailed T-test in (Figure 6C), (Figure 6D) and (Figure 6F), and P values are shown in each graph. [Figure 6G]Figure 6G shows the mean T2 values (n=3) of control MSCs (same donor, passage 4) treated with TGB-β1 (blue) and IL-1 (red) at different concentrations (10 and 20 mg / ml). [Figure 6H] Figure 6H shows the detection limit of the MRR assay for senescent MSCs. Shown are the mean T2 values (n=3) of MSCs with increasing numbers of cells in microcapillary tubes with MRR for control and TGF-β1 (10 and 20 mg / ml) treated MSCs from the same donor at passage 4. The T2 values (n=3) of PBS in microcapillary tubes are shown as black bars at the bottom of the figure (Figure 6B). [Figure 7A] Figure 7A shows the T2 values of unsorted and sorted MSCs. Large cells (22–26 μm) are sorted MSCs harvested in the first round of sorting, while medium cells (15–22 μm) and small cells (11–15 μm) are harvested in the second round of sorting. [Figure 7B] FIG. 7B shows images of multilineage differentiation (osteogenesis and chondrogenesis) of unsorted and sorted cells. [Figure 8] Figure 8 shows the detection limit of the MRR of senescent MSCs. T2 values for various cell concentrations of control MSCs and MSCs (donor 3, passage 4) treated with TGF-β1 (10 and 20 mg / ml) are shown. The T2 value of PBS is shown as a black bar at the bottom of the figure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0029] (Detailed Description) Cellular senescence is a cellular state in which aging and other external or internal conditions lead to the exit of the cell cycle accompanied by genetic, metabolic, and morphological changes in the cell. (Reference 1) Apart from aging, DNA damage (Reference 10), reactive oxygen species (ROS) (Reference 11), activation of certain oncogenes (Reference 12), and tumor-related stresses such as exposure to interferon-β (Reference 13) can also induce cellular senescence. (Reference 2)
[0030] In addition to in vivo aging observed in tissues, cellular senescence is also observed in cultured cells (Reference 14). For example, mesenchymal stem / stromal cells (MSCs) have been intensively studied in many clinical trials for their application in ischemic, inflammatory, autoimmune, regenerative, and degenerative diseases (Reference 9). However, senescent MSCs pose significant challenges in their clinical application (References 14 and 15). Despite the clinical potential of MSCs, proliferation arrest along with morphological and phenotypic changes are observed in MSC populations after long-term culture in vitro (References 14 and 16-18). Furthermore, MSCs isolated from older donors show higher levels of senescence than younger donors (Reference 19). In senescent MSCs, cells become enlarged and flattened, with sclerosed nuclei and granular cytoplasm (References 3, 14, 18, and 20). Aged MSCs have reduced multilineage differentiation capacity (Refs. 14, 17, 18, and 21) and altered secretory and immunoregulatory functions, reducing their therapeutic value (Refs. 3, 22, and 23).
[0031] The standard method to detect senescent MSCs is histochemical staining for acid lysosomal β-galactosidase (β-gal), a cellular senescence biomarker (Refs. 3 and 24). The staining procedure requires a stable pH (~6), cell fixation, and a long culture period (>12 h). Alternatively, cellular senescence can be detected by estimating the remaining proliferative capacity of MSCs after multiple passages by modified colony-forming unit assay (CFU-f) (Refs. 18, 25, and 26). Real-time polymerase chain reaction (qPCR) can also detect senescence by providing gene expression levels of senescence-associated markers p16, p21, and p53 (Refs. 3, 6, and 27). However, these assays require time-consuming and laborious procedures (Ref. 28). In addition, these methods are destructive end-point assays and are not suitable for quality control of MSCs during cell manufacturing. Therefore, rapid detection methods that can quantify the senescent state of MSCs in real time are important for quality control of cell therapies in regenerative medicine.
[0032] There is significant evidence that iron homeostasis and its dysfunction are associated with aging and related conditions (Refs. 29-33). Cellular iron is expressed as Fe 2+ (reactive, unstable or "free" iron, diamagnetic) or Fe 3+ In iron homeostatic cells, Fe is transported by various iron transport proteins (e.g., transferrin (Tf), TfR1, ferroportin, NCOA4, DMT1) and regulators (e.g., p53, NRF2) (ref. 34). 2+ / Fe 3+ Uptake, balancing, and recycling of iron are maintained and involve many different molecular pathways (Ref. 35). Of note, increasing evidence indicates that increased intracellular iron is a universal feature of the aging phenotype and may serve as a “natural marker” of cellular senescence. Senescent cells can also mobilize iron stores by adjusting iron homeostasis proteins (Ref. 36) and by upregulating iron stores to Fe 2+ Ferritinophagy (reference 37) 3+ By inhibiting the autophagy of bound ferritin, the iron (Fe bound to ferritin) 3+ ) up to 30 times higher. 3+ ) is mediated by labile iron (Fe ) released from ferritinophagy. 2+ ) (Reference 39), and also prevents ferroptosis (Reference 38). 3+ ) could provide a noninvasive means for the detection of cellular senescence.
[0033] Microscale magnetic resonance relaxometry (μMRR) has been previously reported as an efficient method for diagnosing malaria (Ref. 40). Paramagnetic Fe in hemozoin crystals of infected red blood cells (RBCs) is detected. 3+ The increase in magnetic susceptibility of non-infected / healthy RBCs is due to the diamagnetic Fe 2+This caused a faster transverse relaxation (T2) of protons than in the normal state (References 40 and 41). Furthermore, a μMRR-based phenotyping test of oxidative stress responses in the blood of diabetic patients was reported as an alternative to conventional A1c testing (Reference 42). Highly sensitive detection of tumor cells (References 43-45), bacteria (Reference 46), and tuberculosis bacteria (Reference 47) has also been reported using similar μMRR devices with immunomagnetically labeled molecular and cellular targets. As shown herein, the μMRR is a noninvasive, nonlabeled, and rapid method for detecting MSC senescence and can identify MSCs with limited proliferation capacity during MSC manufacturing for cell-derived products, opening the door to a broader adaptation of this method to detect cellular senescence in other cells and tissues.
[0034] The systems and methods described herein are capable of detecting small numbers of cells (<10 5 ) and provides the ability to quantify senescent cells in a test tube with a rapid, non-invasive approach that requires no reagents or sample preparation steps. 3+ Direct quantification of senescent cells correlated unexpectedly well with traditional end-point, time-consuming assays commonly used to measure senescent cells, such as qPCR, Luminex assays, and β-galactosidase staining. Measuring proton resonance relaxation reveals the percentage of senescent cells in a sample. Paramagnetic Fe 3+ (diamagnetic Fe 2+ Since the FeCl2+ (except for FeCl2+) increases the magnetic susceptibility and stimulates proton nuclear relaxation of intracellular water molecules, this measurement is based on the FeCl2+ 3+ Previously, intracellular Fe 2+ Labile iron has been measured by colorimetry and other assays (54), but Fe 2+ Due to the reactivity of Fe 2+ Reliable quantitative detection of Fe in samples has generally been difficult (refs. 55 and 56). 3+ It can be used to quantify the amount of Fe in a sample. 3+ The amount of may be correlated with cellular senescence.
[0035] An apparatus for performing magnetic resonance relaxometry is described, for example, in U.S. Patent No. 10,429,467, which is incorporated by reference in its entirety. As shown in FIG. 1A, the apparatus may include an MRR system. FIG. 1A is a schematic diagram of a magnetic resonance relaxometry (MRR) system 100 according to one embodiment of the present disclosure. The system 100 may include a field-programmable gate array-based (FPGA) radio frequency (rf) spectrometer for controlling the MRR system 100, a first direct digital synthesis module for generating radio frequency pulses, a transmitter (TRANS) for transmitting the generated radio frequency pulses to a radio frequency (rf) probe and a detection coil 110, a receiver (RCVR) for receiving resonance information from the radio frequency probe, a first power amplifier (PA), a preamplifier (p-amp), a duplexer (Dup) for transmitting high power excitation pulses to the radio frequency (rf) probe in a transmit mode and isolating the high power excitation pulses from the receiver during a receive mode, and a magnet system 120. The sample 130 can be placed in a sensor, such as a tube or chamber (e.g., a microcapillary tube), which can be placed in an RF detection coil. In many embodiments, the FPGA-based radio frequency (rf) spectrometer can include a pulse programmer (PPG) configured to control the FPGA-based radio frequency (rf) spectrometer and a second direct digital synthesis (DDS). The second DDS can generate a fixed intermediate frequency (IF). The first DDS can be configured to generate a variable desired frequency.According to one aspect of the present disclosure, the FPGA-based spectrometer can use the designs described in Takeda K. (2007), "A highly integrated FPGA-based nuclear magnetic resonance spectrometer," Rev Sci Instrum 78(3):033103 and / or Takeda K. (2008) "OPENCORE NMR: open-source core modules for implementing an integrated FPGA-based NMR spectrometer," Journal of Magnetic Resonance 192(2):218-229, the teachings of these two references are incorporated by reference in their entireties.
[0036] To facilitate the processing of information to and from the MRR system 100, the FPGA-based radio frequency (rf) spectrometer is connectable to at least one external electronic device including, for example, a personal computer, a mobile phone and / or a portable electronic tablet. The connection between the MRR system 100 and the at least one external electronic device can be via at least one of USB, HDMI, and / or wireless connection means such as Wi-Fi and / or Bluetooth.
[0037] In a conventional NMR system, the main cost of the equipment is the superconducting magnet (or permanent magnet) and the radio frequency (rf) spectrometer. According to one aspect of the present disclosure, the cost of the entire system can be less than $2500, with the majority of the cost being the FPGA chips ($1000 each), external GHz clocks ($250 each), DDS (Analog-Device: AD9858, $400 each), 1 watt power amplifier ($100), preamplifier ($50), receiver (RCVR) (AD8343, $4 each), transmitter (TRANS) (AD834, $20 each, and AD8343), and USB (FT2232D, $10 each). In parentheses are the costs of the main electronic components used. Other peripheral components such as pin connectors (e.g., SMA), capacitors, rf switches, rf transformers, and rf filters are less than $10 each.
[0038] The MRR system 100 is adaptable to operate in a variety of modes to detect NMR active nuclei such as protons, fluorine, phosphorus, and carbon. The magnetic field used in each mode in which the MRR system 100 operates varies depending on which nuclide is being detected. Depending on the mode of operation, the MRR system 100 can operate in a magnetic field of about 0.1-3 Tesla (T), which corresponds to about 1-150 MHz. For example, when the MRR system 100 is operating in a proton NMR mode, the magnetic field is about 0.76 T, which corresponds to a proton NMR frequency of about 31.9 MHz.
[0039] The MRR system 100 can be controlled by an FPGA-based radio frequency (rf) spectrometer consisting of a pulse programmer and a second DDS. Compared to CMOS technology, FPGAs have the advantage of being reprogrammable. FPGA-based radio frequency (rf) spectrometers can be programmed using tools and software provided by vendors such as Altera Corporation, San Jose, Calif., USA, and Xilinx, Inc., San Jose, Calif., USA. In an exemplary embodiment, the FPGA chip can include an EP3C80F780C8N (Altera Cyclone III) embedded in a breadboard (ACM-202-80C8, Human Data, Japan). The chip has 81,000 logic elements and can generate three independent if outputs when fully utilized.
[0040] The pulse programmer can generate a high power excitation rf pulse. The generated rf pulse then passes through a first power amplifier, which generates optimized rf power for approximately 1-1000 microseconds to effectively excite all nuclei. The high power rf pulse is transmitted to an rf probe, as further described herein.
[0041] In an exemplary operation, the powers used for liquid-state and solid-state NMR are about 0.1W-10W, and about 100W-1000W, respectively. Although a “strong” power amplifier is often essential for MRR systems, such “strong” power amplifiers are bulky and require high power consumption, which creates serious constraints for field operation. For example, a novel and lightweight 1-watt power amplifier can be constructed with a 4 cm × 4 cm printed circuit board. A solenoid-type microcoil (inner diameter 700-1000 μm, e.g., 750, 800, 850, 900 or 950 μm) can be further employed to generate a strong oscillating magnetic field B1 and pick up signals from free induction decay (FID) or spin echo. By employing a duplexer, the high-power excitation if pulses transmitted to the rf probe in the transmit mode can be separated from the receiver or detection coil 110 during the receive mode. The FID / spin echo is then amplified by a preamplifier (AMP-75+, Mini Circuits, USA) with a gain of 20 dB and a noise figure of 2.83, and finally filtered by an appropriate low-pass filter before being sent to the receiver circuit. The FID is the observable NMR signal produced by a non-equilibrium nuclear spin magnetization rotating around a static magnetic field (conventionally the z-axis). This non-equilibrium magnetization can be induced by applying a resonant radio frequency pulse close to the Larmor frequency of the nuclear spins. The spin echo is a refocusing pulse with one 90 degree reversal followed by a 180 degree pulse reversal on resonance.
[0042] The magnet system 120 is portable and lightweight (e.g., about 60 g) and can be configured to generate a high static magnetic field. The magnet system 120 can include at least one magnet disposed adjacent to the rf probe. Alternative embodiments include having at least two magnets disposed adjacent to the rf probe. The rf probe can be disposed between the at least two magnets. The magnet system 120 can include permanent magnets and / or electromagnets. Permanent magnets used in the magnet system 120 can include, for example, neodymium-based magnets.
[0043] The detection region of the magnetic resonance relaxometry device can contain a sample volume of less than about 1 μL for detection. For example, the sample can be provided in a sensor, such as a capillary tube, or a microcapillary tube, or a chamber. Enclosing the sample from the surrounding environment can reduce exposure to oxygen and other substances that may adversely affect the ability of the magnetic resonance relaxometry device to detect senescent cells.
[0044] As described herein and based on the above device description, a method for detecting senescent cells can include loading a liquid sample containing a plurality of cells into a sensor, placing the sensor containing the liquid sample in a detection coil of a magnetic resonance relaxometry device, and determining a T2 value to detect the amount of senescent cells in the liquid sample. Details of determining the T2 value to detect the amount of senescent cells are described below. For example, the T2 value may decrease as the number of senescent cells increases. In certain circumstances, determining T2 can include measuring the magnetic susceptibility index of cells.
[0045] Current μMRR setups are only suitable for measurements of cell suspensions in liquid samples, for example. A μMRR setup can be designed for adherent cells on cell culture plates. The devices, systems, and methods described herein facilitate the removal of senescent cells from cell populations by simplifying the identification process of senescent cells, and the approach can be used in the development and improvement of cell therapies by combining it with cell manipulation techniques.
[0046] In certain instances, the amount of senescent cells in a liquid sample can be determined by comparison with a reference sample. The device can be calibrated to quickly and reliably measure the amount of senescent cells in a liquid sample. Alternatively, the device can compare two samples to measure the relative amount of senescent cells in a liquid sample. For example, two samples can be distinguished as having a high and a low relative concentration of senescent cells.
[0047] In certain instances, the amount of senescent cells in a liquid sample may be proportional to the concentration of ferritin in the liquid sample. As described below, the unexpected relationship between the amount of ferritin in a liquid sample and the amount of senescent cells in a liquid sample is one feature that facilitates using a magnetic resonance relaxometry device to monitor, measure, or determine the presence of senescent cells in a sample.
[0048] One method to determine the T2 value to detect the amount of senescent cells involves measuring the Fe 3+ In certain circumstances, determining T2 may include quantifying the amount of Fe. In certain circumstances, determining T2 may include measuring the content of other paramagnetic or ferromagnetic ions in the cells, such as copper, specifically copper ions. Other paramagnetic or ferromagnetic ions may include cobalt, nickel, or manganese, cobalt ions, nickel ions, or manganese ions. The magnetic resonance relaxometry device may measure the amount of Fe 3+ For example, determining the T1 or T2 value can include providing a pulse train for a period of less than 5 minutes, less than 4 minutes, less than 3 minutes, less than 2 minutes, or less than 1 minute.
[0049] Various approaches may be taken to improve the accuracy of detecting senescent cells. For example, determining the T1 or T2 value may include acquiring and averaging multiple scans. Up to 100 (or more) scans may be averaged. The number of scans may be less than 80, less than 70, or less than 60. More typically, 10 to 50 scans may be averaged. At least, under certain circumstances, 2 scans, 4 scans, 5 scans, 8 scans, 10 scans, 12 scans, 14 scans, 16 scans, 18 scans, 20 scans, 22 scans, 24 scans, 26 scans, 28 scans, or 30 scans may be averaged. In certain circumstances, the T1 relaxation time may be used in combination with the T2 value to determine whether senescent cells are present in the sample.
[0050] The devices, systems, and methods described herein can be used to monitor or analyze senescence of many different cell types. Identifying senescent cells in a cell population can purify or purify the population to remove senescent cells and improve the productivity of the cell population in a desired application, such as therapy. For example, the cells can include stem cells or progenitor cells. For example, the stem cells or progenitor cells can include mesenchymal stromal cells (MSCs), hematopoietic stem cells (HSCs), or induced pluripotent stem cells (iPSCs). For example, mesenchymal stromal cells (MSCs) can be more effectively used in a desired cell therapy.
[0051] The above system can be used to improve the efficacy of mesenchymal stromal cells to a patient. The method of improving efficacy can include detecting senescent cells in a sample as described above, and enriching the cells in the sample to reduce the number of senescent cells in the sample. The cell separation device can be a cell separation system including a membrane, a sequestrant for removing senescent cells, or a microfluidic device. For example, enriching the cells can include passing the sample through the cell separation device.
[0052] A cell separation device, such as a microfluidic spiral path device, can be used to separate senescent cells from non-senescent cells in a sample. The cell separation device can include a microfluidic cell sorter, an inertial focusing device, a microfluidic filtration device, a centrifugal flow device, a deterministic lateral displacement (DLD) chip, a tangential flow microfiltration device, or a combination thereof. The cell separation device can remove senescent cells based on monitoring the senescent cells. For example, the cell separation device can remove senescent cells from a cell batch (e.g., a cell batch from which a liquid sample was taken) based on detecting the amount of senescent cells.
[0053] 1B, the systems described herein can include a magnetic resonance relaxometry device 200 and a cell separation device 240. For example, a system for detecting senescent cells can include a magnetic resonance relaxometry device configured to detect an amount of senescent cells in a liquid sample and a cell separation device that reduces the amount of senescent cells in the liquid sample based on an output from the magnetic resonance relaxometry device.
[0054] We describe the non-invasive and rapid detection of senescent MSCs using magnetic resonance relaxometry. As shown in Figure 3A, we unexpectedly discovered that the chemical nature of iron ions differs between normal and senescent cells. Normal cells maintain iron homeostasis mediated by numerous iron transporters and iron-binding proteins. Senescent cells are characterized by a paramagnetic Fe 3+ (inactive form of iron) accumulation. For example, normal cells have Fe 2+ and Fe 3+ However, senescent cells have a higher Fe 3+ Accumulate.
[0055] As shown in Figure 3B, the CPMG (Carr-Purcell-Meiboom-Gill) pulse sequence for measuring the T2 value can function efficiently in the inhomogeneous magnetic field generated by the permanent magnet of the MRR. A train of radio frequency pulses is irradiated to the proton nuclei with a resonance frequency of 21.65 MHz with an inter-echo time interval of t echo, and thousands of echoes are repeated until the echo relaxes over time. The height of the echo that decays over time is called the transverse relaxation time T2.
[0056] As shown in Figure 3C, the MRR system can be composed of a portable permanent magnet that provides a strong magnetic field. A homemade radio frequency (RF) detection probe is connected to the RF spectrometer. For T2 measurement, MSC samples (young / proliferating / senescent MSCs) in a microcapillary tube can be placed in the RF detection coil. The microcapillary tube contains 4 μl of MSC sample in a 4 mm detection range of the RF detection coil. The generally required cell number is 60,000 MSCs in the detection volume. The bright areas are the crysseals to seal the microcapillary tube. On the right side, the images of young and senescent MSCs are shown. 1 H spin-spin relaxation time T2 is shown, and T2 is decreased in aged MSCs compared to young MSCs.
[0057] result MRR assay confirms high levels of senescence in large MSCs enriched by size sorting using a spiral microfluidic device
[0058] In preclinical and clinical trials, the formation of senescence in MSC cultures often reduces the therapeutic efficacy of the cells. Previously, cell size, along with other biophysical properties, was identified as a noninvasive marker to distinguish MSC phenotypes (References 48 and 49). Small MSCs are generally multipotent MSCs, whereas large MSCs tend to have limited proliferation and differentiate more prominently into the osteogenic lineage. Large MSCs sorted by inertial microfluidic devices were found to exhibit a senescent phenotype with limited proliferation capacity and longer doubling times compared to small MSCs (Reference 50) (Figures 4A-4F). MRR assays indicate that large MSCs are more senescent based on size sorting using a spiral microfluidic device. Using the same microfluidic device, MSCs were sorted into three size groups: unsorted, small (11–15 μm), medium (15–22 μm), and large (22–26 μm) (see Figures 4A and 4B). The size-sorted cells were then analyzed using a μMRR (Figure 4C). That is, MSCs were added to a microcapillary tube and placed in the radio frequency (RF) detection coil of the μMRR device for T2 measurements. MRR analysis of sorted MSCs showed a decrease in T2 values from small to large cells (Figure 4C), indicating that the proton nuclear relaxation of water, which is ~2000 ms in pure water, was reduced by 100 ms, which is the maximum allowable time for the paramagnetic iron (Fe) in senescent MSCs. 3+ ) impurities significantly decreased the expression levels of senescence-associated markers p16 and p21 (measured by qPCR) in large cells compared to the medium and small groups (Figure 4D). Furthermore, β-gal staining (Figure 4E) strongly correlated with both MRR and qPCR results. Consistent with the lower T2 values measured by μMRR, higher intensity β-gal staining was observed in the large group cells and the unsorted group cells. These results suggest that Fe-gal expression in senescent cells is significantly decreased by senescence. 3+ This supports previous reports of the preservation of T2 relaxation in 36 cells, because the faster T2 relaxation is due to the presence of paramagnetic Fe 3+This is due to increased content. Secretion of molecules associated with the senescence-associated secretory phenotype (SASP) was also measured in unsorted and size-sorted MSC subpopulations (small, medium, and large) (Figure 4D). High expression of key secretory markers associated with the SASP was observed in larger cell MSCs. See, for example, Lu Yin, Zheng Yang, et al., Biomaterials, 240, 119881 (2020), incorporated by reference in its entirety.
[0059] MRR-based senescence measurements correlate with changes in the multilineage differentiation capacity of MSCs from different donors
[0060] MRR analysis measures changes in multilineage differentiation in MSCs from different passages and donors. A key therapeutic quality of MSCs is their ability to undergo multilineage differentiation into cell lineages such as adipocytes, chondrocytes, and osteoblasts. MSCs from different donors show variability in their multilineage differentiation capacity, which has been an important and poorly understood limitation in achieving consistent quality control of therapeutic MSCs. Here, we analyzed MSCs cultured in vitro up to passage 3 from five different donors (D1–D5; see Methods for donor description). For MRR analysis, 6 × 10 MSCs were added to each T2 experiment. 4 Normalized cell counts of 10 ...
[0061] MRR analysis shows that serial passaging of MSCs increases cellular senescence
[0062] It is possible to correlate the MRR with standard assays. During in vitro culture of MSCs, cellular senescence tends to increase during serial passaging. Senescent cells may affect the proliferation and differentiation capacity of MSCs and thus the quality of cells for clinical use. It is therefore important to rapidly identify and potentially remove senescent cells from each passage of MSC culture (Reference 50). Next, MSCs from donor 1 were analyzed under in vitro culture conditions from serial passages P3 to P8. Using the μMRR, the T2 values of normalized concentrations of MSCs from each passage are shown in Figure 6G. The highest T2 values of MSCs were observed in early passages, but these levels gradually decreased in later passages. MSCs from later passages, which had a greater proportion of senescent cells based on the intensity and number of cells showing β-gal staining, showed the lowest T2 values (Figure 6H). Similarly, qPCR of cell cycle inhibition markers p16 and p21 showed the highest expression in cells from late passages compared to early passages (Figure 6E).
[0063] Senescence detection by immunofluorescence assay and MRR
[0064] To directly correlate the cell status with the MRR T2 values, proliferation and senescence were measured simultaneously. MSCs from the same donor were serially passaged to passages 3, 5, and 6. As a positive control for senescent cells, cells at passage 3 were also treated with doxorubicin (DOX). Doxorubicin (DOX) is a chemotherapeutic agent that generates DNA damage and reactive oxygen species, inducing senescence in tumor cells. To measure DNA synthesis, EdU (5-ethynyl-2'-deoxyuridine) was used as an indicator of active cell proliferation (shown in green). In contrast, senescent cells are known to accumulate γ-H2AX foci (shown in red). Proliferation (Pf) and senescence (Sn) indices were calculated from these images and plotted, respectively (Figure 6C and Figure 6D). MRR experiments of cells from all passages and DOX-treated cells were also performed, and the T2 values in each condition are shown (Figure 6F). From the staining images and the graph of Pf / Sn index, there were more proliferative cells (EDU) in P3. Pf gradually decreased in the later passages (P5 and P6) and was the lowest in DOX-treated cells. The Sn index showed the opposite trend, and more senescent cells (γ-H2aX) were observed in P6 and DOX-treated cells compared with P3 and P5. These results were strongly consistent with the measurements of T2 (Figure 6F), supporting that the MRR assay is a robust method to non-invasively detect senescent cells. In addition, there was a higher percentage of β-gal stained cells in the later passage (P6), which was consistent with the results of T2 from the respective passages. Similarly, qPCR (Figure 6E) in which high expression of p16 and p21 was observed in MSCs from P6 supported the measurements of μMRR.
[0065] Senescence induction by cytokine treatment
[0066] Cytokines such as transforming growth factor-β1 (TGFβ1) and interleukin-1 (IL-1) induce senescence in MSCs. TGFβ1 is a TGF family member that controls many cell functions, including proliferation and cell death (References 51 and 52). IL-1 is a proinflammatory cytokine whose expression is associated with the SASP (Reference 53). Therefore, we treated MSCs with different concentrations (10 ng and 20 ng / ml) of TGFβ1 and IL-1 and measured them using the mMRR approach. The T2 values of TGFβ1- and IL-1-treated cells decreased with increasing cytokine concentrations. Senescent cells were more abundant in TGF-β1-treated cells than in IL-1-treated cells (Figure 8), which was also confirmed by the decreased T2 values in IL-1-treated cells compared with TGF-β1-treated cells.
[0067] Since MSC donors vary in their proliferation capacity, it is important to determine the limit of detection (LOD) of the MRR assay in terms of cell number. For all μMRR experiments, the normalized cell number was 6 × 10 in a 4 μl volume in a microcapillary tube. 4 Here, as shown in Figure 6H and Figure 8, the cell concentration was further reduced to 4 × 10 for μMRR detection. 4 , 2×10 4 , 1×10 4 The LOD was analyzed by reducing the number of cells to 10. MSCs were treated with different concentrations (10 and 20 mg / ml) of TGFβ1 to induce senescence, and these cells were harvested for MRR detection. TGF-β1-treated and untreated MSCs were reduced to 1, 2, and 4 (× 10) in a detection volume of 4 μl. 4 A batch of 1 × 10 cells was analyzed in the MRR. The T2 value of PBS was also compared to the T2 values of MSCs (treated and untreated). In this analysis, the T2 value of 1 × 10 cells was compared to the T2 values of untreated MSCs and PBS. 4 Even at the lowest cell concentrations, we show significant differences in T2 values of senescent MSCs. Collectively, the data described herein suggest that MRR can be used to non-invasively measure the presence of senescent cells in heterogeneous cultures, which may be employed to improve bulk culture of clinical-grade cell therapy products such as MSCs.
[0068] A new method for quantifying senescent cells in vitro has been established. This method is rapid, non-invasive, and requires a small number of cells (<10 5 ), and does not require any reagent or sample preparation steps. 3+ Direct quantification of paramagnetic Fe correlated unexpectedly well with traditional end-point, time-consuming assays commonly used to measure senescent cells, such as qPCR, Luminex assays, and β-galactosidase staining. 3+ (diamagnetic Fe 2+ Since the FeCl2+ (except for FeCl2+) increases the magnetic susceptibility and stimulates proton nuclear relaxation of intracellular water molecules, this measurement is based on the FeCl2+ 3+ Previously, intracellular Fe 2+ Labile iron has been measured by colorimetry and other assays (54), but Fe 2+ Due to the reactivity of Fe 2+ Reliable quantitative detection of Fe has generally been difficult (refs. 55 and 56). 3+ Ferritin is often used as a surrogate marker for the quantification of ferritin (57). Ferritin contains up to 4500 atoms of Fe. 3+ Ferritin is a large (~480 kDa) protein complex that can accommodate iron, but its concentration varies depending on the amount of Fe stored in the cell. 3+ ICP-MS quantification of total iron concentration (58) is the current standard for iron quantification, but it does not correlate well with accumulated Fe 3+ may not be accurately reflected.
[0069] In contrast to traditional iron quantification methods, the MRR is uniquely positioned to advance general iron biology. The μMRR allows for complete non-invasive phenotyping of senescent cells and allows for downstream biological and functional measurements of other indicators on the same cells. This ability allows for robust and direct correlations to be made between the MRR and other biochemical and functional measurements. This approach is potentially transformative for the field, especially given the lack of consensus on cell surface markers specific to senescent cells.
[0070] In addition, the “iron imaging” modality utilized here is already widely used in MRI T1- and T2-weighted imaging (Refs. 59–62). Thus, findings from MRR quantification of cellular senescence can be easily compared with in vivo pathology. Given that the resolution of modern MRI approaches is less than 100 μm (Ref. 63), noninvasive detection of senescent cells in living tissues may be feasible in the future. Most importantly, the ability to quantify the degree of senescence in MSCs will uniquely enable the therapeutic application of MSCs. The quality variation of MSCs is mainly due to the different degrees of senescence, and donor-dependent quality variation of MSCs remains a significant unsolved bottleneck. The μMRR is envisioned as a rapid, noninvasive quality screening tool for MSCs in culture-based production processes.
[0071] In this study, the multilineage differentiation capacity of MSCs from different donors also correlated well with the MRR results, with the highest T2 values measured from MSCs with strong multilineage differentiation capacity. This technique will be useful for screening MSCs with the highest proliferation and differentiation capacity in a patient-specific manner in real time. This new bioengineering modality can also be applied to optimize the biomanufacturing of MSCs or other cell therapy products. For example, the MRR can be used to monitor cell cultures in real time in such a way that senescent cells can be removed using microfluidic sorting (Ref. 50). Thus, this approach may overcome a major bottleneck in the field to produce higher grade MSCs and cell products for therapeutic applications.
[0072] Methods and Materials MSC culture
[0073] Bone marrow-derived mesenchymal stem cells (MSCs) were purchased from Lonza Pte Ltd and Rooster Bio Inc. Cells were cultured in low glucose Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% glutamax, and 1% penicillin / streptomycin (Thermo Fisher Scientific, Singapore) at an initial cell density of 1500 cells / cm at 37°C in a CO2: 5% atmosphere. 2MSCs were grown on tissue culture plates (TCP) at 100°C for 3 min. The medium was changed every 2 days, and cells were harvested at 80% confluency for further experiments or subculture. During cell harvesting, cells were incubated with 0.25% trypsin-EDTA (Thermo Fisher Scientific, Singapore) for 3 min. Cell numbers were calculated by trypan blue exclusion using a disposable hemocytometer (INCYTO, Korea). Unless otherwise stated, MSCs from passage 3 (P3) to P5 were used for further experiments. Senescence induction of MSCs was performed by treating them with medium containing 5, 10, or 20 ng / ml TGF-β1 for 3 days. For doxorubicin (DOX) treatment, cells were cultured at 1500 cells / cm. 2 and incubated with 1 μM doxorubicin (Sigma) for 24 h at 37° C. Afterwards, the medium was removed and fresh medium was added to the cells and incubated for 24 h before analysis.
[0074] MSC sorting by inertial spiral microchannel device
[0075] The inertial spiral microchannel device was designed and fabricated in the same way as previously described (50). The device has eight loops with radii decreasing from 12 mm to 4 mm and a trapezoidal cross section with a width of 580 μm, inner 85 um, and outer height of 133 μm. It has one inlet for the introduction of the cell suspension to be sorted and two outlets for the harvesting of the sorted cells. The design was engraved into a micromachined aluminum mold (Whits Technologies Inc., Singapore) and the device was cast from polydimethylsiloxane (PDMS) with a 10:1 ratio of base to hardener mixture (Sylgard 184, Dow Corning Inc., USA).
[0076] Prior to sorting, MSCs were resuspended in culture medium at 1–2 million cells / ml and loaded into a syringe (Thermo Fisher Scientific, Singapore) connected to Tygon tubing (Spectra Teknik Pte Ltd., Singapore). The tubing was inserted into the inlet of the device, and two separate tubes were inserted into the outlets to collect the sorted cells. A syringe pump (PHD2000, Harvard Apparatus Inc., USA) was used to control the flow rate of the cell suspension in the device. Two serial sorts were performed to separate MSCs into three populations with different sizes. The first sort was performed at 3.5 ml / min, with the cells collected at the inner outlet being the largest subpopulation (22–26 μm). The cells collected at the inner outlet were subjected to a second sort at 1.5 ml / min, where the cells collected at the inner and outer outlets were sorted into medium-sized subpopulations (15–22 μm) and smallest subpopulations (11–15 μm), respectively. Unsorted MSCs were used as a control in this experiment. Separation in the inertial spiral microchannel device was visualized in real time by an inverted microscope (IX71, Olympus Co., Japan) equipped with a high-speed CCD camera (Phantom v9, Vision Research Inc., USA).
[0077] MRR measurement
[0078] The MRR consists of a portable permanent magnet with B = 0.5 T (Metrolab Instruments, Plan-les-Ouats, Switzerland) and a tabletop NMR console (Kea Magritek, Wellington, New Zealand). 1H MRR measurements were performed at a resonant frequency of 21.65 MHz inside the magnet. A single-resonant proton MRR probe with a detection microcoil with an inner diameter of 900 μm was used to accommodate the MRR sample in a microcapillary tube (outer diameter: 1,500 μm, inner diameter: 950 μm) (22-260-950, Fisherbrand, Waltham, MA, USA). In the MRR probe, the electronics and coil were mounted on a single printed circuit board (Figure 3C). (Ref. 40) All experiments were performed at 26.3 °C inside the magnet, maintained by a temperature controller (RS components, UK).
[0079] In all MRR experiments, unless otherwise stated, a normalized concentration of MSCs (3 × 10 5 MSC samples were spun down at 300g for 5 min and the supernatant was aspirated. The pellet was suspended in 20 μl of PBS and loaded into a 4 mm long microcapillary tube. The microcapillary tube was sealed with a crysseal and attached to a coil for MRR measurements. The proton transverse relaxation rate T2 was measured by a standard CPMG (Carr-Purcell-Meiboom-Gill) pulse program (refs. 64 and 65) (Figure 3B). The transmitter power output was maintained at 12.5 mW with a single 90° pulse of 16 μs pulse length for all T2 measurements. A CPMG pulse train with an inter-echo time of 60 μs and an echo number of 4000 was used in all experiments. A recycle delay of 2 s was used, sufficient for all spins to return to thermal equilibrium. For signal averaging, 24 scans were performed in all experiments.
[0080] Real-time polymerase chain reaction (qPCR) analysis
[0081] Total RNA was extracted with the RNeasy Mini kit (Qiagen, USA) according to the manufacturer's protocol. RNA concentration was measured using a NanoDrop UV-vis spectrophotometer (NanoDrop Technologies, USA). Then, RNA was analyzed by iScript TM200ng of total RNA was reverse transcribed using a cDNA synthesis kit (Biorad Laboratories, USA). Real-time PCR was performed using the SYBR Green system with the primers shown in Table 1. Real-time PCR was performed at 95°C for 10 min and 40 cycles of amplification, including a denaturation step at 95°C for 15 s and an extension step at 60°C for 1 min, using an ABI 7500 real-time PCR system (Applied Biosystem, USA). Gene expression levels were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and referenced to the respective control group, using the formula: 2 -ΔΔCt The calculation was carried out using
[0082] Table 1. Real-time PCR primers
[0083] [Table 1]
[0084] Conditioned medium and ELISA
[0085] Size-sorted MSCs were seeded in T75 flasks and allowed to attach overnight before removing the medium the next day. Cells were washed once with PBS and cultured in serum-free medium for 48 h at 37 °C and CO2: 5%. The medium was then harvested and centrifuged at 4500 x g for 15 min to remove cellular debris. Supernatants were collected, concentrated to 500 μl with an Amicon Ultra 15 filter (3 kDa cut-off membrane) and stored at -80 °C before analysis. Cell numbers in each condition were determined to normalize the concentration values of the analytes (MCP-1, IL-6, IL-8, TGF-β1) obtained using Luminex®-based multiplex assays (R&D Systems, Inc.) according to the manufacturer's instructions. All samples were analyzed in technical duplicates and performed on two different donors. Data were acquired on a MAGPIX reader (Millipore) and concentrations were derived from the measured mean fluorescence intensity (MFI) using standard curves fitted using a five-parameter logistic regression (SSL5) using Milliplex Analyst software (Millipore).
[0086] In vitro multilineage differentiation
[0087] MSCs were seeded in 24-well plates and allowed to attach overnight before removing the medium, which was then replaced with specific differentiation medium for osteogenesis and adipogenesis (STEMCELL Technologies) according to the manufacturer's protocol. Osteogenic induction was confirmed by Alizarin Red S staining (ScienCell) for calcium deposition, and adipogenic differentiation was confirmed by Oil Red O staining (Sigma) for the detection of lipid droplets. For chondrogenesis, MSCs were seeded at 1 × 10 in 15 ml tubes. 6 Cells / pellet were pelleted at 300 x g for 5 min. Chondrogenic medium (STEMCELL Technologies) was added to the pellet and the medium was changed every other day for 3 weeks before glycosaminoglycan staining with Safranin O.
[0088] Senescence assay
[0089] MSCs were seeded in 6-well plates at an initial cell seeding density of 1500 cells / cm. 2 Cells were seeded at 4 °C and cultured for 3–5 days. Senescent β-galactosidase staining kit (Sigma Aldrich) was used to identify senescent cells according to the manufacturer's protocol. Briefly, cells were fixed for 10 min at room temperature and cultured overnight at 37 °C in staining solution containing X-gal. Cells that stained positively with a blue precipitate as a result of X-gal substrate cleavage indicated senescent cells.
[0090] Immunofluorescence and confocal microscopy
[0091] To detect SA-βgal together with another senescence marker (γ-H2AX foci) (66) and the proliferation marker 5-ethynyl-2′-deoxyuridine (Edu) in cells, a protocol was carried out as previously described (67). Briefly, cells were cultured with 10 μM (Edu) (Click-it® Edu Alexa Fluor® 488 Imaging Kit, Invitrogen) for 24 h, then fixed with 10% neutral buffered formalin (Sigma) and stained for SA-βGal using the components of the staining kit according to the manufacturer's instructions (#9860, Cell Signaling Technology). Edu labeling was then detected according to the manufacturer's protocol (Invitrogen).
[0092] For immunostaining, cells were washed with PBS and incubated in blocking buffer (PBS containing 0.5% bovine serum albumin) for 1 h, followed by incubation with mouse anti-phospho-histone H2A.X (Ser139) antibody (05-636, Millipore) in blocking buffer at 4°C overnight. Cells were then stained with Rhodamine Red. TMThe cells were incubated with SA-βGal-conjugated secondary antibody (Jackson Immuno Research Laboratories) for 1 h, washed three times with PBS, and counterstained with NucBlue (Hoechst 33342)-containing mounting solution (Invitrogen). Images were acquired with an FV1200 confocal microscope using a 20x objective (Olympus). Stained SA-βGal cells were also visualized by phase contrast microscopy.
[0093] The following references, many of which are cited herein, are incorporated by reference in their entireties:
[0094] References
[0095] [Table 2] TIFF2024541966000004.tif220170TIFF2024541966000005.tif218170TIFF2024541966000006.tif219170TIFF20245419660 00007.tif221170TIFF2024541966000008.tif221170TIFF2024541966000009.tif215170TIFF2024541966000010.tif232170
[0096] The details of one or more embodiments are set forth in the accompanying drawings and detailed description. Other features, objects, and advantages will become apparent from the detailed description, drawings, and claims. Although a number of embodiments of the invention have been described, it will be understood that various modifications can be made without departing from the spirit and scope of the invention. It should also be understood that the accompanying drawings are not necessarily to scale and that they depict various features and underlying principles of the invention in somewhat simplified form.
Claims
1. 1. A method for detecting senescent cells, comprising: loading a liquid sample containing a plurality of cells into a sensor; placing the sensor containing the liquid sample within or near a detection coil of a magnetic resonance relaxometry device; and To detect the amount of senescent cells in the liquid sample, 2 measuring a value.
2. The method of claim 1 , wherein the sensor is a tube or a chamber.
3. 2. The method of claim 1, wherein the amount of senescent cells in the liquid sample is determined relative to a reference sample.
4. 2. The method of claim 1, wherein the amount of senescent cells in the liquid sample is proportional to the concentration of ferritin in the liquid sample.
5. To detect the amount of senescent cells, 2 Determining the value of Fe in the liquid sample 3+ The method of claim 1, further comprising quantifying the amount of
6. To determine whether senescent cells are present in the sample, 1 The relaxation time is T 2 The method of claim 1 , wherein the method is used in combination with a value.
7. Said T 1 or T 2 The method of claim 6 , wherein determining the value includes delivering a pulse train for a period of less than one minute.
8. Said T 1 or T 2 The method of claim 6, wherein determining the value comprises acquiring and averaging between 2 and 70 scans.
9. Said T 2 The method of claim 1 , wherein the value decreases as the number of senescent cells increases.
10. The method of claim 1 , wherein the cells comprise mesenchymal stromal cells.
11. The method of claim 1 , wherein the cells comprise hematopoietic stem cells.
12. The method of claim 1 , wherein the cells comprise induced pluripotent stem cells.
13. 10. The method of claim 1, wherein the detection volume of the magnetic resonance relaxometry device comprises a sample volume of less than about 1 μL.
14. T 2 2. The method of claim 1, wherein determining comprises measuring the paramagnetic or ferromagnetic ion content of the cells.
15. The method of claim 14 , wherein the paramagnetic or ferromagnetic ions comprise copper.
16. 1. A method for improving availability of stem or progenitor cells to a patient, comprising: Detecting senescent cells in a sample by the method of any one of claims 1 to 15; enriching cells in the sample to reduce the number of senescent cells in the sample.
17. 17. The method of claim 16, wherein enriching for cells comprises passing the sample through a cell separation device, thereby separating senescent cells from non-senescent cells in the sample.
18. The method of claim 16 , wherein the cell separation device comprises a microfluidic spiral path.
19. 1. A system for detecting senescent cells, comprising: A magnetic resonance relaxometry device configured to detect the amount of senescent cells in a liquid sample; and the system comprising a cell separation device for reducing the amount of the senescent cells in the liquid sample based on output from the magnetic resonance relaxometry device.
20. The system of claim 19 , wherein the liquid sample is contained within a microcapillary.
21. 20. The system of claim 19, wherein the liquid sample is taken from a batch of cells.
22. 22. The system of claim 21, wherein the cell separation device removes senescent cells from the cell batch based on detecting the amount of senescent cells.
23. 20. The system of claim 19, wherein the cell separation device comprises a microfluidic cell sorter, an inertial focusing device, a microfluidic filtration device, a centrifugal flow device, a deterministic lateral displacement (DLD) chip, a tangential flow microfiltration device, or a combination thereof.
24. 20. The system of claim 19, wherein the cell separation device comprises a microfluidic spiral path device.
25. The magnetic resonance relaxometry device detects the amount of senescent cells in the liquid sample. 2 20. The system of claim 19 configured to measure a value.
26. 20. The system of claim 19, wherein the amount of senescent cells in the liquid sample is proportional to a ferritin concentration in the liquid sample.
27. The magnetic resonance relaxometry apparatus detects the amount of senescent cells. 2 The liquid sample is configured to measure Fe values. 3+ The system of claim 19, further comprising quantifying the amount of
28. 20. The system of claim 19, wherein the senescent cells comprise mesenchymal stromal cells (MSCs), hematopoietic stem cells (HSCs), or induced pluripotent stem cells (iPSCs).
